A synthetic version of GHRH, Tesamorelin appears to mimic the action of growth hormone. The 44-amino acid chain of Tesamorelin, derived from GHRH and used to promote growth hormone production and secretion, is considered to enhance stability and duration by adding a trans-3-hexenoic acid group compared to natural GHRH.

Tesamorelin is primarily involved in research related to lipodystrophy in HIV, which may increase growth hormone production and release in the organism. Tesamorelin is now the subject of extensive research into its potential for improving composition and reducing fat.

Tesamorelin Peptide Potential

The synthetic peptide Tesamorelin is one of the family of substances called growth hormone-releasing hormones (GHRHs).

Due to its structural similarity, Tesamorelin's action is hypothesized to be quite similar to that of endogenous GHRH. It has been hypothesized to promote the secretion of growth hormone (hGH) by functioning as an analog to growth hormone-releasing factor.

Lipodystrophy is a condition characterized by alterations in fat distribution and metabolism; it is often seen in antiretroviral procedures (ART) in the context of HIV infection.

What makes hGH so significant?

Growth hormone (hGH) is considered to be crucial because it is believed to play a role in almost every activity that involves making or repairing new tissue. It is thought to encourage cell proliferation and division.

That implies it may impact development and play a role in maturation. But at its core, the organism appears to utilize growth hormone during processes related to tissue repair and physical strain, in the renewal of skin cells, and the development of cells affiliated with the immune system.

Hormone replacement procedures (HRT) has been linked to many crucial functions:
● Proliferation of muscle cells
● Lipolysis, which converts fat into energy,
● Production of proteins
● Development of organs
● Core temperature regulation
● Glucose level stability

The amount of growth hormone (hGH) in the blood is considered to decrease over time, which is why, in part, the organism's healing and regeneration processes slow down.

Tesamorelin Peptide and hGH

Tesamorelin, like Pralmorelin and EP1572, is a GHRH hypothesized to stimulate the organism to release more hGH, which may result in larger concentrations. If hGH levels are high, processes related to tissue repair, muscle and body mass composition may be better regulated by the organism.

Tesamorelin and Ipamorelin

Studies suggest that peptides such as Tesamorelin and Ipamorelin may potentially promote growth hormone secretion (GH). However, researchers must consider a few important distinctions when planning their study. To start, Tesamorelin's alleged action in directly tied to physiological action associated with muscle cell developement and fat cell strorage, and may have downstream impacts in adipose tissue and fat, and has been studied in relation to lipodystrophy in HIV.

Pig studies in Ipamorelin have indicated that the selective growth hormone secretagogue Ipamorelin may potentially increase GHRH stimulation without changing plasma levels of cortisol or adrenocorticotropic hormone (ACTH). Research on rats has also indicated that it may promote the production of growth

hormones and increase weight
Although there is some overlap in the ability of both peptides to increase GH levels, researchers should keep these two distinctions in mind.

Tesamorelin Peptide Potential

Despite Tesamorelin's long history, researchers are now elucidating its precise function. Many studies have focused on its specific impacts, such as its possible impact on HIV. However, studies examining its complete properties are few in other domains. Nonetheless, Tesamorelin's possible impacts are shed light on in the literature:

● Researchers' knowledge of hGH's effects on muscle development is believed to be fairly well-established, and there is some speculation that Tesamorelin may have a similar impact. Researchers have hypothesized that Tesamorelin may greatly enhance the density and growth of muscles affected with HIV.

●Tesamorelin seems to decrease the quantity of visceral adipose tissue (VAT) in HIV-infected tissues, previously exposed to antiretroviral compounds, according to two randomized, placebo-controlled studies. This is believed to lead to fat reduction.

●Investigations purport that Tesamorelin may reduce cardiovascular risk associated in cases of HIV infections and may potentially "significantly decrease" fat in adipose tissues, which might lead to a lower risk of cardiovascular disease overall.

●Nerve Injury. Regenerating nerve cells is not easy, but there is some speculation that approaches based on growth hormone (GH), such as Tesamorelin, may impact this.

●Cognitive improvement. Research indicates that Tesamorelin may have the potential to halt processes in the brain that are considered to lead to cognitive loss associated with dementia.

Tesamorelin Peptide Conclusion

Researchers looking for a place to find peptides for sale online are encouraged to try Core Peptides. Please remember that none of the compounds mentioned in this paper have been approved for human or animal consumption and should, therefore, not be acquired or utilized by unlicensed individuals.

References

[i] Patel, A., Gandhi, H., & Upaganlawar, A. (2011). Tesamorelin: A hope for ART-induced lipodystrophy. Journal of Pharmacy And Bioallied Sciences, 3(2), 319.

[ii] Dhillon, S. (2011). Tesamorelin. Drugs, 71(8), 1071-1091.


[iii] Florini, J. R. (1987). Hormonal control of muscle growth. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine, 10(7), 577-598.

[iv] Editorial, A. (2004). Pralmorelin: GHRP 2, GPA 748, Growth Hormone-Releasing Peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs in R & D, 5, 236-239.

[v] Broglio, F., Boutignon, F., Benso, A., Gottero, C., Prodam, F., Arvat, E., ... & Muccioli, G. (2002). EP1572: a novel peptidomimetic GH secretagogue with potent and selective GH-releasing activity in man. Journal of Endocrinological Investigation, 25(8), RC26-RC28.

[vi] Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16. PMID: 20554713.

[vii] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.

[viii] Adrian, S., Scherzinger, A., Sanyal, A., Lake, J. E., Falutz, J., Dubé, M. P., ... & Brown, T. T. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. The Journal of Frailty & Aging, 8(3), 154-159.